Ambu Valuation
Is AMBU B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of AMBU B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: AMBU B (DKK127.6) is trading above our estimate of fair value (DKK79.51)
Significantly Below Fair Value: AMBU B is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for AMBU B?
Other financial metrics that can be useful for relative valuation.
What is AMBU B's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 33.90b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 6.5x |
Enterprise Value/EBITDA | 45.5x |
PEG Ratio | 3.6x |
Price to Earnings Ratio vs Peers
How does AMBU B's PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 28.6x | ||
DEMANT Demant | 22.9x | 12.4% | DKK 58.1b |
EMBLA Embla Medical hf | 34.5x | 17.3% | DKK 14.5b |
COLO B Coloplast | 40.2x | 13.3% | DKK 198.4b |
002223 Jiangsu Yuyue Medical Equipment & Supply | 16.9x | 14.8% | CN¥34.2b |
AMBU B Ambu | 75.5x | 21.2% | DKK 33.9b |
Price-To-Earnings vs Peers: AMBU B is expensive based on its Price-To-Earnings Ratio (75.5x) compared to the peer average (28.6x).
Price to Earnings Ratio vs Industry
How does AMBU B's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: AMBU B is expensive based on its Price-To-Earnings Ratio (75.5x) compared to the European Medical Equipment industry average (29.8x).
Price to Earnings Ratio vs Fair Ratio
What is AMBU B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 75.5x |
Fair PE Ratio | 40.9x |
Price-To-Earnings vs Fair Ratio: AMBU B is expensive based on its Price-To-Earnings Ratio (75.5x) compared to the estimated Fair Price-To-Earnings Ratio (40.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | DKK 127.60 | DKK 125.50 -1.6% | 19.1% | DKK 145.00 | DKK 76.00 | n/a | 6 |
Oct ’25 | DKK 130.00 | DKK 125.50 -3.5% | 19.1% | DKK 145.00 | DKK 76.00 | n/a | 6 |
Sep ’25 | DKK 127.95 | DKK 126.40 -1.2% | 21.9% | DKK 160.00 | DKK 76.00 | n/a | 5 |
Aug ’25 | DKK 140.60 | DKK 117.00 -16.8% | 25.0% | DKK 138.00 | DKK 59.00 | n/a | 5 |
Jul ’25 | DKK 136.55 | DKK 117.00 -14.3% | 25.0% | DKK 138.00 | DKK 59.00 | n/a | 5 |
Jun ’25 | DKK 131.40 | DKK 111.20 -15.4% | 24.9% | DKK 138.00 | DKK 59.00 | n/a | 5 |
May ’25 | DKK 111.95 | DKK 107.20 -4.2% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
Apr ’25 | DKK 113.55 | DKK 107.20 -5.6% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
Mar ’25 | DKK 121.45 | DKK 107.20 -11.7% | 26.4% | DKK 130.00 | DKK 52.00 | n/a | 5 |
Feb ’25 | DKK 111.60 | DKK 105.00 -5.9% | 26.7% | DKK 130.00 | DKK 52.00 | n/a | 5 |
Jan ’25 | DKK 105.20 | DKK 85.67 -18.6% | 26.2% | DKK 115.00 | DKK 47.00 | n/a | 6 |
Dec ’24 | DKK 91.94 | DKK 85.67 -6.8% | 26.2% | DKK 115.00 | DKK 47.00 | n/a | 6 |
Nov ’24 | DKK 69.86 | DKK 89.40 +28.0% | 28.2% | DKK 120.00 | DKK 53.00 | n/a | 5 |
Oct ’24 | DKK 73.86 | DKK 95.60 +29.4% | 25.6% | DKK 120.00 | DKK 53.00 | DKK 130.00 | 5 |
Sep ’24 | DKK 83.56 | DKK 96.00 +14.9% | 25.3% | DKK 120.00 | DKK 53.00 | DKK 127.95 | 5 |
Aug ’24 | DKK 99.16 | DKK 101.80 +2.7% | 27.0% | DKK 135.00 | DKK 59.00 | DKK 140.60 | 5 |
Jul ’24 | DKK 111.65 | DKK 102.60 -8.1% | 26.9% | DKK 135.00 | DKK 59.00 | DKK 136.55 | 5 |
Jun ’24 | DKK 107.50 | DKK 102.60 -4.6% | 26.9% | DKK 135.00 | DKK 59.00 | DKK 131.40 | 5 |
May ’24 | DKK 105.50 | DKK 101.60 -3.7% | 28.4% | DKK 135.00 | DKK 55.00 | DKK 111.95 | 5 |
Apr ’24 | DKK 102.75 | DKK 96.25 -6.3% | 30.8% | DKK 135.00 | DKK 55.00 | DKK 113.55 | 4 |
Mar ’24 | DKK 101.35 | DKK 104.60 +3.2% | 30.2% | DKK 140.00 | DKK 55.00 | DKK 121.45 | 5 |
Feb ’24 | DKK 99.14 | DKK 87.80 -11.4% | 20.6% | DKK 110.00 | DKK 65.00 | DKK 111.60 | 5 |
Jan ’24 | DKK 89.00 | DKK 83.40 -6.3% | 19.5% | DKK 110.00 | DKK 65.00 | DKK 105.20 | 5 |
Dec ’23 | DKK 91.70 | DKK 83.20 -9.3% | 19.8% | DKK 110.00 | DKK 64.00 | DKK 91.94 | 5 |
Nov ’23 | DKK 88.88 | DKK 76.50 -13.9% | 11.7% | DKK 85.00 | DKK 64.00 | DKK 69.86 | 4 |
Oct ’23 | DKK 66.42 | DKK 76.50 +15.2% | 11.7% | DKK 85.00 | DKK 64.00 | DKK 73.86 | 4 |
Analyst Forecast: Target price is lower than the current share price.